Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 22,541 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
lecozotan SR (SRA-333)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more
Conditions
HIV/AIDS
Interventions
PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Orlando, Florida • Boston, Massachusetts • Houston, Texas
No Longer Available No phase listed Expanded access

Expanded Access Program for Revumenib

NCT05918913
Conditions
Relapsed/Refractory Acute Leukemia
Interventions
Revumenib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
6 Months and older
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, SAVR Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
2,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
55
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 46 more
Completed Phase 2 Interventional Results available

Ph II Study of Azacitidine in Myelofibrosis

NCT00569660
Conditions
Myelofibrosis
Interventions
Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Schizophrenia
Interventions
TAK-063 20 mg, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, Epoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
44
States / cities
Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
Interventions
Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
30
States / cities
Duarte, California • La Jolla, California • Stanford, California + 23 more
Conditions
Hepatitis C
Interventions
Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
35
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more
Conditions
HIV Infections
Interventions
enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Conditions
Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
Homoharringtonine, Imatinib Mesylate
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Motor Recovery
Interventions
tACS Sham, tACS 10Hz, tACS 20Hz
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Conditions
Relapsed/Refractory B-cell Malignancies
Interventions
UBX-303061
Drug
Lead sponsor
Ubix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Ann Arbor, Michigan • Canton, Oklahoma • Houston, Texas
Conditions
Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Vulvar Squamous Cell Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
193
States / cities
Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 130 more
Conditions
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Conditions
Hypoxemia, Acute Respiratory Failure
Interventions
SuperNO2VA nasal positive airway pressure devic, Supplemental oxygen
Device
Lead sponsor
Vyaire Medical
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Myeloma
Interventions
Topotecan, Cyclophosphamide, Melphalan, Peripheral Blood Stem Cells
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor
Interventions
Proton Beam
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Advanced Solid Tumors
Interventions
NTS071
Drug
Lead sponsor
Nutshell Therapeutics (Shanghai) Co., LTD.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • Fairfax, Virginia
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Ischemic Stroke
Interventions
Elezanumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 90 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Long Beach, California • Washington D.C., District of Columbia + 18 more
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more